216087-92-2

Usage

Uses

Used in Pharmaceutical Industry:
Phenyl(tetrahydro-2H-pyran-4-yl)Methanol is used as a key intermediate in the synthesis of tricyclic compounds that serve as bromodomain and BET inhibitors. Bromodomain and extra-terminal (BET) proteins are epigenetic readers that play a crucial role in regulating gene expression. Inhibition of these proteins can have therapeutic benefits in treating various diseases, including cancer and inflammatory disorders, by modulating gene expression and cellular processes.
The specific application of phenyl(tetrahydro-2H-pyran-4-yl)Methanol in the preparation of tricyclic compounds highlights its importance in the development of novel therapeutic agents targeting bromodomain and BET proteins. This application underscores the potential of phenyl(tetrahydro-2H-pyran-4-yl)Methanol as a valuable building block in medicinal chemistry and drug discovery efforts.

Upstream product

• 50675-18-8 3,4,5,6-tetrahydro-2H-pyran-4-carbaldehyde 
• 639468-72-7 phenyl(tetrahydro-2H-pyran-4-yl)methanone 
• 5123-13-7 5,5-dimethyl-2-phenyl-1,3,2-dioxaborinane 
• 100-58-3 phenylmagnesium bromide 
• 3174-74-1 dihydropyran 
• 100-52-7 benzaldehyde 
• 100-59-4 phenylmagnesium chloride 
• 14774-37-9 (tetrahydro-2H-pyran-4-yl)methanol 
• 156353-01-4 N-methoxy-N-methyltetrahydro-2H-pyran-4-carboxamide 
• 101765-10-0 tetrahydro-4-(methoxymethylene)-2H-pyran 
• 40191-32-0 tetrahydro-2H-pyran-4-carbonylchloride 
• 5337-03-1 tetrahydro-2H-pyran-4-carboxylic acid 
• 29943-42-8 Tetrahydro-4H-pyran-4-one 

Downstream Products

• 1800340-40-2 (-)-(S)-2-[3-(dimethyl-1H-1, 2,3-triazo1-5-yl)-5-[oxan-4-yl(phenyl)-methyl]-5H-pyrido [3,2-b] indol-7-yl]propan-2-ol 
• 1800345-36-1 (S)-(tetrahydro-2H-pyran-4-yl)(phenyl)methanol 
• 1800345-36-1 (R)-(tetrahydro-2H-pyran-4-yl)(phenyl)methanol 

Relevant academic research and scientific papers

Reductive Arylation of Amides via a Nickel-Catalyzed Suzuki–Miyaura-Coupling and Transfer-Hydrogenation Cascade

We report a means to achieve the addition of two disparate nucleophiles to the amide carbonyl carbon in a single operational step. Our method takes advantage of non-precious-metal catalysis and allows for the facile conversion of amides to chiral alcohols via a one-pot Suzuki–Miyaura cross-coupling/transfer-hydrogenation process. This study is anticipated to promote the development of new transformations that allow for the conversion of carboxylic acid derivatives to functional groups bearing stereogenic centers via cascade processes.

SUBSTITUTED 2-AMINO-PYRAZOLYL-[1,2,4]TRIAZOLO[1,5A] PYRIDINE DERIVATIVES AND USE THEREOF

Provided herein are 2-amino-pyrazolyl-[ 1,2,4]triazolo [1,5a]pyridine derivatives. Such compounds are useful, for example, for the treatment and/or prevention of neurodegenerative diseases or disorders such as ophthalmological neurodegenerative disorders. This disclosure also features compositions containing the same as well as methods of using and making the same.

TRICYCLIC COMPOUND FOR BROMODOMAIN-CONTAINING PROTEIN INHIBITOR AND PREPARATION, PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF

The present applicationpresent application relates to a compound represented by Formula (III) or a pharmaceutically acceptable salt, solvent compound, active metabolite, crystal polymorph, ester, isomer, or prodrug thereof. The application further provides a pharmaceutical composition comprising the compound represented by Formula (III) and a use thereof for preparing a bromodomain inhibitor for preventing or treating various diseases, such as inflammation and cancer, related to the bromodomain.

Branch-Selective Addition of Unactivated Olefins into Imines and Aldehydes

Radical hydrofunctionalization occurs with ease using metal-hydride hydrogen atom transfer (MHAT) catalysis to couple alkenes and competent radicalophilic electrophiles. Traditional two-electron electrophiles have remained unreactive. Herein we report the reductive coupling of electronically unbiased olefins with imines and aldehydes. Iron catalysis allows addition of alkyl-substituted olefins into imines through the intermediacy of free radicals, whereas a combination of catalytic Co(Salt-Bu,t-Bu) and chromium salts enables a branch-selective coupling of olefins and aldehydes through the formation of a putative alkyl chromium intermediate.

Aromatic-ring-containing compound, preparation method thereof, pharmaceutical composition and application thereof

The invention discloses an aromatic-ring-containing compound, a preparation method thereof, a pharmaceutical composition and application. The present invention provides the aromatic-ring-containing compound represented by a formula 1, a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a tautomer thereof or a solvate thereof, and the aromatic-ring-containing compound can be effectively bounded to bromodomains of BRD4, BRD3, BRD2, and BRDT in BET family to regulate transcription of downstream gene c-myc and related target genes of the c-myc so as to regulate downstream signalingpathways to play specific roles including treatment of diseases such as inflammatory diseases, cancer, and AIDS. Some of the compounds have high activity, and have good cell activity and metabolic stability, so that the compounds can be an effective drug for treating tumors.

COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS

The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.

The "reverse-tethered" ruthenium (II) catalyst for asymmetric transfer hydrogenation: Further applications

The attachment of a tethering group from the basic nitrogen atom to the arene ligand of a ruthenium(II) catalyst greatly improves its ability to catalyze asymmetric transfer hydrogenation (ATH) reactions. In this paper, we describe further applications of this versatile system to an extended substrate range.

Syntheses and Binding Studies of New [(Aryl)(aryloxy)methyl]piperidine Derivatives and Related Compounds as Potential Antidepressant Drugs with High Affinity for Serotonin (5-HT) and Norepinephrine (NE) Transporters

In a wide search program toward new, efficient, and fast-acting antidepressant drugs, we have prepared series of new compounds having an (aryl)(aryloxy)methyl moiety linked directly or through a methylene chain to different substituted and unsubstituted cycles (isoquinoline, piperazine, piperidine, tetrahydropyran, or cyclopentane). These compounds have been evaluated for their affinities for serotonin (5-HT) transporter (SERT) and 5-HT1A and 5-HT2A receptors. Racemic mixtures of 4-[(aryl)(aryloxy)methyl]piperidine derivatives showed much higher affinity values for SERT than fluoxetine and resulted in lack of affinity for 5-HT 1A and 5-HT2A receptors. Some of these racemic mixtures were resolved to their enantiomers and tested for binding to norepinephrine (NE) transporter (NET), dopamine (DA) transporter (DAT), and α2 receptor. Several of these enantiomers [(-)-15b, (-)-15j, (-)-15t, (+)-15u] displayed a dual binding profile with affinities for SERT and NET with K i i = 1.9 and 13.5 nM, respectively), and further pharmacological characterization is in progress for its evaluation as a antidepressant.